David Planchard, MD, PhD, Department of Medical Oncology, Thoracic Unit, Institut Gustave Roussy, discusses a phase II trial examining the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in pretreated patients with 

-mutant advanced non—small cell lung cancer (NSCLC).

In the study, patients continued treatment with the doublet regimen until disease progression or unacceptable toxicity. The overall response rate, which was the primary endpoint of the trial, was 63% with assessments by both investigators and an independent review committee, Planchard says. The disease-control rate was approximately 80%, which demonstrates that the combination can benefit this patient population.

Among the responders, 50% of patients had ongoing responses, Planchard adds. Additionally, the median progression-free survival rate was 9.7 months, according to investigator assessment.

Videos

David Planchard, MD, PhD, Department of Medical Oncology, Thoracic Unit, Institut Gustave Roussy, discusses a phase II trial examining the combination of dabrafenib and trametinib in pretreated patients with BRAF V600E-mutant advanced non–small cell lung cancer (NSCLC).

David Planchard, MD, PhD

Articles

Dr. Planchard on Dabrafenib/Trametinib Combo in Advanced NSCLC